Kamada Ltd., a global biopharmaceutical company specializing in plasma-derived therapies, will announce its financial results for the second quarter and first half ended June 30, 2026, on August 12 before U.S. markets open. The company will host a conference call at 8:30am ET to discuss the results and answer investor questions. Kamada focuses on growing through its proprietary specialty plasma products, distribution partnerships, plasma collection operations in the U.S., and strategic mergers and acquisitions. This update is important for investors tracking the company's progress in expanding its product portfolio and plasma business.
Blade Resources has been approved to list its shares on the Canadian Securities Exchange, with trading starting around September 14, 2026. Prismo Metals owns 6,755,000 shares, representing about 24% of Blade, following a transaction involving the Hot...
Coinbase CEO Brian Armstrong predicts Bitcoin may reach $400,000 by 2030, a 420% increase from current levels, based on its four-year cycle pattern and recent market bottom. Key upcoming events like the CLARITY Act vote and the next Bitcoin halving s...
Ripple has upgraded its $1 billion-acquired Ripple Treasury platform by integrating GSmart AI agents to assist with liquidity management, cash flow forecasting, reconciliation, and risk assessment. These AI agents provide recommendations but require ...
Gemfields Group Limited held a commercial-quality emerald auction from August 24 to September 10, 2026, generating $29.6 million in sales. The auction achieved a record average price of $9.72 per carat, up from $7.46 in the previous sale, despite sel...
Pan African Resources has completed a feasibility study for its Soweto Tailings Retreatment project in South Africa, aiming to increase annual gold production at its Mogale complex to around 100,000 ounces. The project involves retreating tailings wi...
